Univest
Univest
  • Markets

Sudeep Pharma vs Nifty 50: Returns Compared

  • October 12, 2026
  • Posted by: Kunal Singla
  • Category: Market
No Comments
Sudeep Pharma vs Nifty 50: Returns Compared

Sudeep Pharma share price Rs 1,050.30 on NSE. Sudeep Pharma vs Nifty 50 over 6 months: +72.22% vs -6.36%. 52-week high Rs 1,378.00, low Rs 524.05.

Quick Answer

Sudeep Pharma vs Nifty 50 gives a mixed picture: Sudeep Pharma has beaten the index in 2 of 3 time frames, and its 6-month return of +72.22% compares with -6.36% for the Nifty 50. Over the past month, Sudeep Pharma fell 12.68% while the Nifty 50 fell 3.75%, a gap of 8.93 percentage points against it. At Rs 1,050.30, Sudeep Pharma is 23.8% below its 52-week high of Rs 1,378.00 and 100.4% above its 52-week low of Rs 524.05. Returns use NSE closing prices to 9 October 2026, and past performance does not indicate future results.

Sudeep Pharma vs Nifty 50 is a comparison that looks different depending on the time frame chosen. Sudeep Pharma trades on the NSE under the symbol SUDEEPPHRM, and its 1-month return of -12.68% compares with -3.75% for the Nifty 50 over the same period.

The Sudeep Pharma vs Nifty 50 comparison matters because Sudeep Pharma is a single stock exposed to its own business and sector developments, while the Nifty 50 spreads risk across 50 large companies. This article lines up Sudeep Pharma share price performance against the Nifty 50 across 1 month, 3 months and 6 months, using NSE closing data up to 9 October 2026. NSE price history for Sudeep Pharma begins on 28 November 2025, so the table covers only the time frames with a full trading record.

Also read – SIS vs Nifty 50: Share Price Performance Compared

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Sudeep Pharma vs Nifty 50: Performance at a Glance
  • Latest Close and 52-Week Range: Sudeep Pharma and the Nifty 50
  • Why the Sudeep Pharma vs Nifty 50 Gap Exists
  • Sudeep Pharma vs Nifty 50: Has Sudeep Pharma Beaten the Benchmark?
  • Risks of the Sudeep Pharma vs Nifty 50 Comparison
  • Conclusion
    • Has Sudeep Pharma outperformed the Nifty 50 in the last 6 months?
    • How does Sudeep Pharma vs Nifty 50 look over the last month?
    • What is the Sudeep Pharma share price today compared to Nifty 50?
    • What is the 52-week high and low of Sudeep Pharma?
    • Why does Sudeep Pharma show bigger price swings than the Nifty 50?
    • Is Sudeep Pharma a good long-term investment compared to a Nifty 50 index fund?

Sudeep Pharma vs Nifty 50: Performance at a Glance

The table below sets out the Sudeep Pharma vs Nifty 50 performance across the available time frames, measured from NSE closing prices up to 9 October 2026.

Time Frame Sudeep Pharma Return Nifty 50 Return Difference
1 Month -12.68% -3.75% -8.93 pp
3 Months +27.42% -6.97% +34.39 pp
6 Months +72.22% -6.36% +78.58 pp

On the Sudeep Pharma vs Nifty 50 scorecard, Sudeep Pharma has beaten the index over the latest 6-month window, returning +72.22% against -6.36% for the Nifty 50, a difference of 78.58 percentage points. That is also the widest gap anywhere in the table. The direction differs over the past six months: Sudeep Pharma moved up while the Nifty 50 moved down.

Check the Univest Screener for live Sudeep Pharma and Nifty 50 data

Latest Close and 52-Week Range: Sudeep Pharma and the Nifty 50

Instrument Latest Close 52-Week High 52-Week Low Vs 52-Week High
Sudeep Pharma Rs 1,050.30 Rs 1,378.00 Rs 524.05 -23.8%
Nifty 50 22,520.45 26,373.20 22,179.90 -14.6%

Sudeep Pharma closed at Rs 1,050.30 on 9 October 2026, which is 23.8% below its 52-week high of Rs 1,378.00 and 100.4% above its 52-week low of Rs 524.05. The Nifty 50 closed at 22,520.45, 14.6% below its own 52-week high of 26,373.20, so the benchmark has also been through a drawdown over the past year.

Why the Sudeep Pharma vs Nifty 50 Gap Exists

Sudeep Pharma can move very differently from the Nifty 50 because it carries concentrated exposure to its own business and sector cycle, while the index blends 50 companies across banking, IT, energy and consumer sectors. The 52-week range shows it clearly: Sudeep Pharma has traded between Rs 524.05 and Rs 1,378.00, a spread of 163.0% from low to high, against 18.9% for the Nifty 50.

Company-specific triggers such as quarterly results, management commentary and order or capacity announcements can move Sudeep Pharma’s price sharply in either direction, while the Nifty 50’s return reflects the blended earnings of its constituents and is far less exposed to any single company’s news.

Download the Univest iOS App or Univest Android App to track Sudeep Pharma and Nifty 50 live on the go.

Sudeep Pharma vs Nifty 50: Has Sudeep Pharma Beaten the Benchmark?

Yes, over the past six months. Sudeep Pharma returned +72.22% against -6.36% for the Nifty 50, a lead of 78.58 percentage points. Across the three time frames measured, Sudeep Pharma is ahead of the index over 3 months and 6 months and behind it over 1 month.

Risks of the Sudeep Pharma vs Nifty 50 Comparison

Point-to-point returns can mislead, and the Sudeep Pharma vs Nifty 50 comparison is no exception. A different start date would shift every figure in the table above, and past performance does not indicate how either Sudeep Pharma or the Nifty 50 will perform from here.

Also read – SKF India (Industrial) vs Nifty 50: Returns Compared

Sudeep Pharma carries concentrated business and sector risk that a diversified index does not. Its 52-week range of Rs 524.05 to Rs 1,378.00 shows the scale of the swings a single-stock investor has lived with, against a range of 22,179.90 to 26,373.20 for the Nifty 50.

Conclusion

Sudeep Pharma vs Nifty 50 shows Sudeep Pharma ahead of the index in 2 of 3 time frames and behind in the rest, which is why the answer depends on the horizon an investor cares about. Volatility, liquidity and sector concentration deserve as much weight as the return history, and a SEBI-registered advisor can help fit Sudeep Pharma into a wider portfolio.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Has Sudeep Pharma outperformed the Nifty 50 in the last 6 months?

Ans. Yes. Sudeep Pharma returned +72.22% over the past six months while the Nifty 50 returned -6.36%, based on NSE closing prices to 9 October 2026.

How does Sudeep Pharma vs Nifty 50 look over the last month?

Ans. Over the past month Sudeep Pharma has returned -12.68% compared with the Nifty 50’s -3.75%, so in the Sudeep Pharma vs Nifty 50 comparison the stock has been behind over this horizon.

What is the Sudeep Pharma share price today compared to Nifty 50?

Ans. Sudeep Pharma share price closed at Rs 1,050.30 on NSE on 9 October 2026, while the Nifty 50 closed at 22,520.45 in the same session.

What is the 52-week high and low of Sudeep Pharma?

Ans. Sudeep Pharma’s 52-week high is Rs 1,378.00 and its 52-week low is Rs 524.05, based on NSE data. The latest close of Rs 1,050.30 is 23.8% below the high.

Why does Sudeep Pharma show bigger price swings than the Nifty 50?

Ans. Sudeep Pharma carries concentrated exposure to its own sector and business cycle, while the Nifty 50 spreads risk across 50 large companies. Over 52 weeks Sudeep Pharma has traded in a 163.0% low-to-high range against 18.9% for the index, a key reason the Sudeep Pharma vs Nifty 50 return gap varies across time frames.

Is Sudeep Pharma a good long-term investment compared to a Nifty 50 index fund?

Ans. Sudeep Pharma’s suitability depends on an investor’s risk appetite, since single-stock exposure carries higher concentration risk than a diversified Nifty 50 index fund. Long-term investors should weigh the Sudeep Pharma vs Nifty 50 return history alongside the company’s fundamentals and consult a SEBI-registered advisor.



Nifty 50 Stock Market
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply